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ACUTE MYOCARDIAL INFARCTION-THERAPY
Megadose Bolus Heparin as Reperfusion Therapy 
for Acute Myocardial Infarction: Results of the 
HEAP Pilot Study
Freek W.A. Verheugt, Randall C. Marsh, Gerrlt Veen, Jean G.F. Bronzwaer, 
Felix Zijlstra. North Colorado Med Ctr, Greeley, CO; Free University 
Hospital, Amsterdam; University Hospital, Nijmegen; Weezenianden 
Hospital, Zwolle, The Netherlands
Angiography after thrombolysis for acute myocardial Infarction (AMI) shows 
better patency when adjunct intravenous (iv) heparin is used. We wondered, 
if iv heparin alone also induces reperfusion.
In the HEAP (Heparin in Early Patency) pilot study 50 patients (pts) with <  
6  hours (h) signs; (>  2  mm ST f  in >  2 leads) and symptoms of AMI received a 
single Iv bolus of 300 U/kg heparin, a dose usually given by cardiac surgeons 
prior to cardiopulmonary bypass. Doses of bolus heparin given varied from 
10,000 to 40,000 U. Aspirin (160 mg chewed), but no thrombolytic agent was 
given. Patency was assessed by coronary angiography at 90 minutes (min) 
after the heparin bolus.
In 28/50 (56%) pts TIMI flow 2 -3  was seen at 90 min: TIMI flow 3 in 18 
(36%) pts and TIM I flow 2 in 10 (20%) pts. Pts with < 2 h symptoms (n = 
24) had 67% TIMI flow 2 -3  versus 46% in pts with > 2 h symptoms (p =
0.09). Pts with TIM I flow 0—1 underwent direct angioplasty. At 90 min aPTT 
exceeded 120 sec in all pts. No significant bleeding was seen. Aspirin 80 mg 
daily was given, as was heparin (aPTT 2.0-2.5) for 48 h. Predischarge angio 
showed T IM I flow 3 in 15/18 (83%) pts.
Thus, early therapy with high-dose front-loaded heparin alone can induce 
full coronary reperfusion in pts with AMI, especially in early (< 2  h) pts. 
This simple, inexpensive and easily antagonizable AMI treatment seems 
to be an attractive alternative to regular thrombolysis, both in-hospital and 
pre-hospital, and can also be given prior to direct PTCA.
901-2 Failure to Improve Outcome in Suspected Acute
Myocardial Infarction by Pre-Hospital 
Administration of Aspirin
Robert Greenbaum, Martin Flaherty, Koon Lan Chan, Dan Shanlt. 
Cardiovascular Research Unit Edgware General Hospital and The London
Ambulance Accident and Emergency Service, London, UK
1
The ISIS-2 trial has shown that in-hospital treatment of suspected acute 
myocardial infarction (AMI) patients with aspirin is almost as effective as 
treatment with streptokinase in reducing 35 day mortality. We carried out a 
prospective, randomised, non-blind, controlled study of the effect of adminis­
tration of a single oral dose of 300 mg aspirin to patients with suspected AMI 
prior to transportation to hospital on 35 day mortality. The study was carried
out over an eighteen month period by front line ambulance crews based at 
15 London Ambulance Stations. 1850 patients with suspected acute myocar­
dial infarction aged over 30 years were screened for eligibility. 1652 were 
randomised by the ambulance crews. 999 were allocated to a strategy of 
pre-hospital aspirin and 653 allocated to control (no aspirin). 980 (98%) of 
those allocated to the treatment group received the medication. At 35 days 
there were 91 deaths in the aspirin group (9.1%) compared with 56 (8.6%) in 
the control group. The absolute increased risk 0.5% (95% confidence inter­
val -2 ,2 6 %  to 3.3%) was not significant. The majority of deaths were due to 
cardiac causes 77 (85%) in the aspirin group and 47 (84%) in control. There 
were no major side effects attributable to pre-hospital aspirin. During long 
term'24-38 months follow up, there were 248 deaths (24.8%) in the aspirin 
group and 163 (25%) in the control group. This 0.2% reduction in the risk 
of death (95% confidence interval -4 .4 %  to 4.1%) was not significant. We 
conclude that a policy of pre-hospital administration of aspirin to patients with 
suspected acute myocardial Infarction is safe but does not improve outcome.
Early aPTT Measurements Are Not a Surrogate for in 
Vivo Thrombin Inhibition Among Patients Receiving 
Thrombolytic Therapy and Adjunctive 
Anticoagulation
Richard C. Becker, James Hebert, Thomas Hurley, Yunsheng Ma, 
Christopher P. Cannon, for the TIM I 5 Hemostasis and Thrombosis Study 
Group. Thrombosis Research Center, University of Massachusetts Medical 
School, Worcester, MA
The immediate goal of thrombolytic therapy is to rapidly establish and main­
tain physiologic coronary arterial blood flow. Adjunctive anticoagulant therapy 
may be required to achieve optimal reperfuslon; however, the target aPTT  
value has been difficult to establish. In TIMI 5, measures of thrombin ac­
tivity (FPA) and thrombin generation (F1.2) were obtained serially in 246  
patients receiving accelerated tPA and either heparin or hirudin. FPA and 
F1.2 levels at 12 and 24 h did not correlate with aPTT at these time points 
in either heparin or hirudin-treated patients. An aPTT >  90 sec (commonly 
considered high-intensity anticoagulation), was not consistently associated 
with decreased thrombin activity or generation. In fact, the lowest combined 
FPA and F1.2 value was seen with a 12 h aPTT of 60 sec,
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